Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 9/20 | 0.35 |
| ▸ | DRD3 | P35462 | 10/20 | 0.34 |
| ▸ | DRD4 | P21917 | 10/20 | 0.33 |
| ▸ | HTR1A | P08908 | 7/20 | 0.33 |
| ▸ | DRD1 | P21728 | 7/20 | 0.33 |
| ▸ | DRD5 | P21918 | 7/20 | 0.33 |
| ▸ | IL1B | P01584 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | EBP | Q15125 | 1/20 | 0.32 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12921240 | 0.91 | PIM1 (0.35) | PDE4DDRD2DRD3DRD4DRD1 | |
| SCHEMBL12921484 | 0.91 | TSHR (0.35) | PDE4DDRD2DRD3DRD4IL1B | |
| SCHEMBL12921237 | 0.90 | SRD5A1 (0.41) | PDE4DIL1BPIM1PIM2SRD5A1 | |
| SCHEMBL8056114 | 0.86 | PDE4D (0.36) | PDE4DIL1BPIM1PIM2SRD5A1 | |
| SCHEMBL10283466 | 0.86 | PDE4D (0.34) | PDE4DIL1BPIM1PIM2SRD5A1 | |
| SCHEMBL186820 | 0.85 | SRD5A1 (0.43) | PDE4DDRD2IL1BPIM1PIM2 | |
| SCHEMBL8051881 | 0.85 | PDE4D (0.33) | PDE4DIL1BSRD5A1 | |
| SCHEMBL12921334 | 0.85 | PDE4D (0.33) | PDE4DIL1BSRD5A1 | |
| SCHEMBL8064923 | 0.84 | OPRL1 (0.42) | PDE4DDRD2 | |
| SCHEMBL12921481 | 0.83 | SCN9A (0.34) | PDE4DIL1BPIM1PIM2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2610258-B1 | Substituted piperidino dihydrothieno pyrimidines | BOEHRINGER INGELHEIM INT (DE) | 2014-08-27 | — | — | EP | disclosed |
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| US-8754073-B2 | Substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-17 | — | — | US | disclosed |
| EP-2610258-A1 | Substituted piperidino dihydrothieno pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2380891-A1 | Substituted piperidino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2009050248-A1 | SUBSTITUTED PIPERIDINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021501-A1 | SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | DPYD, P2RX1, P2RX5 | PDE4D 2859/4885DRD2 1834/4885DRD3 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.